Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

710 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Active Case Finding for Tuberculosis through TOUCH Agents in Selected High TB Burden Wards of Kolkata, India: A Mixed Methods Study on Outcomes and Implementation Challenges.
Dey A, Thekkur P, Ghosh A, Dasgupta T, Bandopadhyay S, Lahiri A, Sanju S V C, Dinda MK, Sharma V, Dimari N, Chatterjee D, Roy I, Choudhury A, Shanmugam P, Saha BK, Ghosh S, Nagaraja SB. Dey A, et al. Among authors: roy i. Trop Med Infect Dis. 2019 Nov 1;4(4):134. doi: 10.3390/tropicalmed4040134. Trop Med Infect Dis. 2019. PMID: 31683801 Free PMC article.
Factors Associated With Coronary Angiography Performed Within 6 Months of Randomization to the Conservative Strategy in the ISCHEMIA Trial.
Pracoń R, Spertus JA, Broderick S, Bangalore S, Rockhold FW, Ruzyllo W, Demchenko E, Nageh T, Grossman GB, Mavromatis K, Manjunath CN, Smanio PEP, Stone GW, Mancini GBJ, Boden WE, Newman JD, Reynolds HR, Hochman JS, Maron DJ; ISCHEMIA Research Group. Pracoń R, et al. Circ Cardiovasc Interv. 2024 Apr 17:e013435. doi: 10.1161/CIRCINTERVENTIONS.123.013435. Online ahead of print. Circ Cardiovasc Interv. 2024. PMID: 38629312
Physicochemical, structural and biological characterisation of poly(3-hydroxyoctanoate) supplemented with diclofenac acid conjugates - Harnessing the potential in the construction of materials for skin regeneration processes.
Haraźna K, Fricker AT, Konefał R, Medaj A, Zimowska M, Leszczyński B, Wróbel A, Bojarski AJ, Roy I, Guzik M. Haraźna K, et al. Among authors: roy i. Int J Biol Macromol. 2024 Apr 16;268(Pt 1):131476. doi: 10.1016/j.ijbiomac.2024.131476. Online ahead of print. Int J Biol Macromol. 2024. PMID: 38614181
Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-cell nHL Treated with CAR-T.
Karmali R, Machhi R, Epperla N, Shouse G, Romancik JT, Moyo TK, Kenkre VP, Ollila TA, Fitzgerald LA, Hess BT, David KA, Roy I, Zurko JC, Chowdhury SM, Annunzio K, Ferdman R, Bhansali RS, Harris EI, Liu J, Nizamuddin IA, Ma S, Moreira J, Winter JN, Pro B, Stephens DM, Danilov AV, Shah NN, Cohen JB, Barta SK, Torka P, Gordon LI. Karmali R, et al. Among authors: roy i. Blood Adv. 2024 Mar 26:bloodadvances.2023011996. doi: 10.1182/bloodadvances.2023011996. Online ahead of print. Blood Adv. 2024. PMID: 38531057
Subsequent Malignant Neoplasms in Patients Previously Treated with Anti-CD19 CAR T-Cell Therapy.
Melody M, Epperla N, Shouse G, Romancik JT, Allen PB, Moyo TK, Kenkre VP, Ollila TA, Fitzgerald LA, Hess BT, David KA, Herr MM, Odetola O, Lin AY, Moreira J, Ma S, Winter JN, Roy I, Stephens DM, Danilov AV, Shah NN, Barta SK, Cortese MJ, Cohen J, Gordon LI, Karmali R. Melody M, et al. Among authors: roy i. Blood Adv. 2024 Mar 18:bloodadvances.2024012573. doi: 10.1182/bloodadvances.2024012573. Online ahead of print. Blood Adv. 2024. PMID: 38498727 No abstract available.
710 results